Wet AMD patients with poor initial acuity also benefit from bevacizumab treatment

This retrospective review included 44 treatment-naïve wet AMD patients with initial visual acuity of 0.1 decimal or less who were treated with intravitreal Avastin (bevacizumab). After a mean follow-up of 3.9 months, vision improved from baseline in 25 eyes (57 percent), was stable in 10 (23 percent) and decreased in 9 (20 percent). Mean macular thickness was significantly reduced from 332 to 248 µm. The authors conclude that even in with newly diagnosed CNV, visual acuity of 0.1 decimal or less, and active CNV, bevacizumab treatment is beneficial.